Dose reduction for the management of indinavir-related toxicity in human immunodeficiency virus type 1-infected patients in Taiwan: Clinical and pharmacokinetic assessment

Journal of Microbiology, Immunology and Infection

Volumn 38, Issue 1, 2005, Pages 31-34

  Pan, Sung Ching ^a   Hsieh, Szu Min ^a   Hung, Chien Ching ^a,b   Huang, Pei Fong ^a   Chen, Mao Yuan ^a   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Drug toxicity; Human immunodeficiency virus (HIV); Indinavir; Pharmacokinetics; Ritonavir

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; PROTEINASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MONITORING; HAIR LOSS; HEMATURIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LOW BACK PAIN; NAUSEA; NEPHROLITHIASIS; SKIN DISEASE; TAIWAN; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; HIV-1; HUMANS; INDINAVIR; PILOT PROJECTS;

EID: 14744295298     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999;19: 708-12.
3. Piscitelli SC. The role of therapeutic drug monitoring in the management of HIV-infected patients. Curr Infect Dis Reports 2002;4:353-8.
4. Hoetelmans RMW. Therapeutic drug monitoring in HIV disease. J HIV Ther 2001;6:65-7.
5. Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002;16:551-60.
6. Rathbun RC, Rossi DR. Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann Pharmacother 2002;36:702-6.
7. Burger DM, Hugen PW, Aarnoutse RE, Dieleman JP, Prins JM, Van der Poll T, et al. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr 2001;26:218-24.
8. Solas C, Basso S, Poizot-Martin I, Ravaux I, Gallais H, Gastaut JA, et al. High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Synd 2002;29:374-7.
9. Hsieh SM, Yu HY, Chang SC. Simultaneous determination of indinavir, ritonavir and saquinavir in plasma by high-performance liquid chromatography. J Formos Med Assoc 2004;103:191-5.
10. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. March 23, 2004.
11. Casado JL, Perez-Elias MJ, Antela A, Sabido R, Marti-Belda P, Dronda F, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998;12:F131-5.